JAG201 gene replacement therapy available to both child and adult patients is now in Phase I clinical trial.

In 2020 Jennifer Doudna & Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for discovering the revolutionary gene-editing tool CRISPR/Cas9. This article shines a spotlight on their remarkable achievements and addresses current applications and future opportunities for CRISPR/Cas9.

Danish company Novo Holdings has acquired a majority stake in the Austrian-based company Single Use Support, marking a critical stride towards the wider adoption of single-use bioprocessing tools.

A recent study shows that a novel refractometry-based PAT system monitors metabolic activity during CGT production, revealing insights into optimising bioprocesses.

Cell & Gene 2024 Conference Producer Anya Chuykov met with Stephen Sullivan, COO of iPSirius, to discuss the advancements being made by iPSirius, and their unique proprietary technology working to treat aggressive forms of cancer.

Scarlet Therapeutics uses genetic manipulation of red blood cells to carry a higher load of therapeutic proteins to help treat rare metabolic diseases.

A study conducted by the Broad Institute and the Massachusetts Institute of Technology (MIT) demonstrated that when multi-tailed mRNAs were integrated into a CRISPR-Cas9 system they proved to be more efficient gene editors than unmodified mRNA.

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.